GEP201706612B - Methods for the treatment of breast cancer - Google Patents
Methods for the treatment of breast cancerInfo
- Publication number
- GEP201706612B GEP201706612B GEAP201212972A GEAP2012012972A GEP201706612B GE P201706612 B GEP201706612 B GE P201706612B GE AP201212972 A GEAP201212972 A GE AP201212972A GE AP2012012972 A GEAP2012012972 A GE AP2012012972A GE P201706612 B GEP201706612 B GE P201706612B
- Authority
- GE
- Georgia
- Prior art keywords
- breast cancer
- treatment
- methods
- entinostat
- exemestane
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/566—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol having an oxo group in position 17, e.g. estrone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
- A61K31/5685—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/483—Physical analysis of biological material
- G01N33/4833—Physical analysis of biological material of solid biological material, e.g. tissue samples, cell cultures
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Physics & Mathematics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Food Science & Technology (AREA)
- Pathology (AREA)
- Immunology (AREA)
- General Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Optics & Photonics (AREA)
- Biophysics (AREA)
- Hematology (AREA)
- Analytical Chemistry (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Pregnancy & Childbirth (AREA)
- Oncology (AREA)
- Diabetes (AREA)
- Gynecology & Obstetrics (AREA)
- Reproductive Health (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161530873P | 2011-09-02 | 2011-09-02 | |
| US201161532534P | 2011-09-08 | 2011-09-08 | |
| US201161628999P | 2011-11-12 | 2011-11-12 | |
| US201161568110P | 2011-12-07 | 2011-12-07 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| GEP201706612B true GEP201706612B (en) | 2017-02-10 |
Family
ID=47756940
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GEAP201212972A GEP201706612B (en) | 2011-09-02 | 2012-08-31 | Methods for the treatment of breast cancer |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US10226472B2 (pt-PT) |
| EP (2) | EP2751267B1 (pt-PT) |
| JP (2) | JP6195384B2 (pt-PT) |
| KR (1) | KR101956861B1 (pt-PT) |
| CN (3) | CN103906837A (pt-PT) |
| AU (2) | AU2012301616B2 (pt-PT) |
| BR (1) | BR112014005080A2 (pt-PT) |
| CA (1) | CA2847348A1 (pt-PT) |
| EA (1) | EA201201474A1 (pt-PT) |
| ES (1) | ES2663407T3 (pt-PT) |
| GE (1) | GEP201706612B (pt-PT) |
| HK (1) | HK1254859A1 (pt-PT) |
| MX (1) | MX358254B (pt-PT) |
| UA (6) | UA124238U (pt-PT) |
| WO (1) | WO2013033656A1 (pt-PT) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013033656A1 (en) | 2011-09-02 | 2013-03-07 | Syndax Pharmaceuticals, Inc. | Methods for the treatment of breast cancer |
| KR102337598B1 (ko) * | 2013-05-03 | 2021-12-10 | 신닥스 파마슈티컬스, 인크. | 암 치료 방법 |
| WO2016145294A1 (en) * | 2015-03-12 | 2016-09-15 | The University Of Chicago | Methods for determining prognosis for breast cancer patients |
| EP3345002A4 (en) * | 2015-09-02 | 2019-05-08 | Syndax Pharmaceuticals Inc. | SELECTION OF PATIENTS FOR POLYTHERAPY |
| EP3487492A4 (en) * | 2016-07-20 | 2020-03-11 | Eisai R&D Management Co., Ltd. | USE OF ERIBULIN AND HISTONE DEACETYLASE INHIBITORS FOR THE TREATMENT OF CANCER |
| EP3791185B1 (en) | 2018-05-07 | 2022-12-14 | Syndax Pharmaceuticals, Inc. | Selection of patients for combination therapy |
| KR102212699B1 (ko) | 2019-08-12 | 2021-02-05 | 한국원자력의학원 | 유방암 예방 또는 치료용 조성물 |
| US11636870B2 (en) | 2020-08-20 | 2023-04-25 | Denso International America, Inc. | Smoking cessation systems and methods |
| US11813926B2 (en) | 2020-08-20 | 2023-11-14 | Denso International America, Inc. | Binding agent and olfaction sensor |
| US11828210B2 (en) | 2020-08-20 | 2023-11-28 | Denso International America, Inc. | Diagnostic systems and methods of vehicles using olfaction |
| US12017506B2 (en) | 2020-08-20 | 2024-06-25 | Denso International America, Inc. | Passenger cabin air control systems and methods |
| US11932080B2 (en) | 2020-08-20 | 2024-03-19 | Denso International America, Inc. | Diagnostic and recirculation control systems and methods |
| US11760169B2 (en) | 2020-08-20 | 2023-09-19 | Denso International America, Inc. | Particulate control systems and methods for olfaction sensors |
| US11760170B2 (en) | 2020-08-20 | 2023-09-19 | Denso International America, Inc. | Olfaction sensor preservation systems and methods |
| US11881093B2 (en) | 2020-08-20 | 2024-01-23 | Denso International America, Inc. | Systems and methods for identifying smoking in vehicles |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4410545A (en) | 1981-02-13 | 1983-10-18 | Syntex (U.S.A.) Inc. | Carbonate diester solutions of PGE-type compounds |
| US4328245A (en) | 1981-02-13 | 1982-05-04 | Syntex (U.S.A.) Inc. | Carbonate diester solutions of PGE-type compounds |
| US4409239A (en) | 1982-01-21 | 1983-10-11 | Syntex (U.S.A.) Inc. | Propylene glycol diester solutions of PGE-type compounds |
| US6350458B1 (en) | 1998-02-10 | 2002-02-26 | Generex Pharmaceuticals Incorporated | Mixed micellar drug deliver system and method of preparation |
| WO2008021542A2 (en) * | 2006-08-17 | 2008-02-21 | Cell Signaling Technology, Inc. | Lysine acteylation sites |
| CA2726734C (en) * | 2007-06-06 | 2014-10-07 | University Of Maryland, Baltimore | Hdac inhibitor ms-275 and aromatase inhibitors for the treatment of cancer |
| WO2008154382A1 (en) | 2007-06-06 | 2008-12-18 | University Of Maryland, Baltimore | Hdac inhibitors and hormone targeted drugs for the treatment of cancer |
| US20100305167A1 (en) * | 2007-11-19 | 2010-12-02 | Syndax Pharmaceuticals, Inc. | Administration of an Inhibitor of HDAC |
| WO2012106473A2 (en) | 2011-02-02 | 2012-08-09 | Genentech, Inc. | Dosing for treatment with anti-egfl7 antibodies |
| JP6024025B2 (ja) | 2011-05-02 | 2016-11-09 | イミューノメディクス、インコーポレイテッドＩｍｍｕｎｏｍｅｄｉｃｓ， Ｉｎｃ． | 少容量投与用のアロタイプ選択抗体の限外濾過濃縮 |
| WO2013033656A1 (en) | 2011-09-02 | 2013-03-07 | Syndax Pharmaceuticals, Inc. | Methods for the treatment of breast cancer |
| CH706458B1 (fr) | 2012-04-30 | 2017-05-15 | Granit Tech Sa | Procédé de cimentation pour le stockage de déchets. |
-
2012
- 2012-08-31 WO PCT/US2012/053551 patent/WO2013033656A1/en active Application Filing
- 2012-08-31 UA UAU201711132U patent/UA124238U/uk unknown
- 2012-08-31 AU AU2012301616A patent/AU2012301616B2/en active Active
- 2012-08-31 CA CA2847348A patent/CA2847348A1/en not_active Abandoned
- 2012-08-31 UA UAU201711135U patent/UA124240U/uk unknown
- 2012-08-31 CN CN201280053368.3A patent/CN103906837A/zh active Pending
- 2012-08-31 CN CN202110805646.7A patent/CN114053284A/zh active Pending
- 2012-08-31 CN CN201711383372.7A patent/CN107982270A/zh active Pending
- 2012-08-31 ES ES12827061.8T patent/ES2663407T3/es active Active
- 2012-08-31 GE GEAP201212972A patent/GEP201706612B/en unknown
- 2012-08-31 US US14/342,354 patent/US10226472B2/en active Active
- 2012-08-31 EP EP12827061.8A patent/EP2751267B1/en not_active Revoked
- 2012-08-31 UA UAA201512370U patent/UA149007U/uk unknown
- 2012-08-31 UA UAA201213781U patent/UA123212U/uk unknown
- 2012-08-31 JP JP2014528678A patent/JP6195384B2/ja active Active
- 2012-08-31 UA UAU201711134U patent/UA124239U/uk unknown
- 2012-08-31 EP EP18152916.5A patent/EP3381454A1/en not_active Withdrawn
- 2012-08-31 KR KR1020147008685A patent/KR101956861B1/ko active IP Right Grant
- 2012-08-31 UA UAU201711136U patent/UA124241U/uk unknown
- 2012-08-31 EA EA201201474A patent/EA201201474A1/ru unknown
- 2012-08-31 BR BR112014005080A patent/BR112014005080A2/pt not_active Application Discontinuation
- 2012-08-31 MX MX2014002515A patent/MX358254B/es active IP Right Grant
-
2017
- 2017-04-21 JP JP2017084847A patent/JP2017149761A/ja active Pending
-
2018
- 2018-05-02 AU AU2018203059A patent/AU2018203059A1/en not_active Abandoned
- 2018-11-01 HK HK18113956.5A patent/HK1254859A1/zh unknown
-
2019
- 2019-01-15 US US16/248,443 patent/US20190343844A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CN103906837A (zh) | 2014-07-02 |
| MX358254B (es) | 2018-08-10 |
| US20140378420A1 (en) | 2014-12-25 |
| EP3381454A1 (en) | 2018-10-03 |
| UA124240U (uk) | 2018-03-26 |
| UA124238U (uk) | 2018-03-26 |
| JP2017149761A (ja) | 2017-08-31 |
| ES2663407T3 (es) | 2018-04-12 |
| AU2012301616B2 (en) | 2018-02-08 |
| KR20140108629A (ko) | 2014-09-12 |
| UA123212U (uk) | 2018-02-26 |
| US20190343844A1 (en) | 2019-11-14 |
| CN107982270A (zh) | 2018-05-04 |
| JP2014525465A (ja) | 2014-09-29 |
| UA124239U (uk) | 2018-03-26 |
| JP6195384B2 (ja) | 2017-09-13 |
| EA201201474A1 (ru) | 2013-08-30 |
| EP2751267A1 (en) | 2014-07-09 |
| CN114053284A (zh) | 2022-02-18 |
| AU2018203059A1 (en) | 2018-05-17 |
| AU2012301616A1 (en) | 2014-04-17 |
| US10226472B2 (en) | 2019-03-12 |
| WO2013033656A1 (en) | 2013-03-07 |
| EP2751267A4 (en) | 2015-01-07 |
| KR101956861B1 (ko) | 2019-03-12 |
| EP2751267B1 (en) | 2018-01-24 |
| UA124241U (uk) | 2018-03-26 |
| UA149007U (uk) | 2021-10-13 |
| BR112014005080A2 (pt) | 2017-03-28 |
| CA2847348A1 (en) | 2013-03-07 |
| MX2014002515A (es) | 2015-05-07 |
| HK1254859A1 (zh) | 2019-07-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GEP201706612B (en) | Methods for the treatment of breast cancer | |
| IL273090B (en) | Methods and preparations for the treatment of cancer | |
| HK1217289A1 (zh) | 使用細菌治療癌症的組合物和方法 | |
| MX366804B (es) | Translocaciones de la r-espondina y sus metodos de uso. | |
| HK1199099A1 (en) | Methods and compositions for the treatment and diagnosis of cancer | |
| MX2016003129A (es) | Terapia de combinacion de anticuerpos contra el csf-1r humano y anticuerpos contralel pd-l1 humano. | |
| EP2714081A4 (en) | METHODS, COMPOSITIONS AND KIT FOR CREAM TREATMENT | |
| MX2016004570A (es) | Uso de inhibidores del bromodominio de cbp/ep300 para la inmunoterapia del cáncer. | |
| MX2015014500A (es) | Terapia de combinacion de anticuerpos contra csf-1r y agonista de tlr9. | |
| EA201400178A1 (ru) | Лечение рака молочной железы | |
| MX370573B (es) | Monoterapia con glucopiranosil lipido a para usarse en el tratamiento del cancer. | |
| EP2688594A4 (en) | METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER | |
| IN2014CN03555A (pt-PT) | ||
| IL238177A0 (en) | Methods and preparations for the treatment of cancer | |
| HK1199290A1 (en) | Methods and compositions for the treatment and diagnosis of breast cancer | |
| MX2012012992A (es) | Metodos de tratamiento. | |
| MX360774B (es) | Antagonistas de progesterona. | |
| EP3004396A4 (en) | Methods and compositions for the treatment of cancer | |
| HK1222869A1 (zh) | 用於治療癌症的針對 的偶聯抗體 | |
| IN2014DN00254A (pt-PT) | ||
| MX2017009281A (es) | Antihistamina para usar en el tratamiento de cancer de seno. | |
| MX2012012744A (es) | Composiciones y metodos para el diagnostico y tratamiento de tumores. | |
| LT2984108T (lt) | Anti-s100a7 antikūnai, skirti vėžio gydymui ir diagnozei | |
| ZA201400488B (en) | Compounds for the treatment of cancers associated with human papillomavirus | |
| UA58160U (ru) | Применение липофлавона в качесте средства для лечения черепно-мозговой травмы |